PLA2G7 and coronary artery disorder: Moreover, none of the variants that were significantly associated with baseline Lp‐PLA2 activity was associated with efficacy endpoints.38 This finding was validated in another genetic study with 261 950 total participants, which identified that both Lp‐PLA2‐lowering alleles and darapladib treatment were not related to CHD risk.77 Altogether, this evidence indicates that Lp‐PLA2 is a reliable biomarker rather than a causal risk factor for CVDs, but this view remains to be confirmed.173